Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting antibodies to the ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results